Figure 1.

Effect of VCX on the proliferation and growth of human breast cancer cells. (A) Human breast cancer cell lines; SKBR-3, MCF-7, and MDA-MB-231 cells were treated for 24 h with a wide range of VCX concentrations. Cell proliferation and viability were determined by Muse^® Count & Viability assay. (B) MDA-MB-231 cells were treated with VCX (10, 25, and 50 μM) for 24 h. Thereafter, the percentages of live, depolarized, and dead cells were determined by Muse^® MitoPotential Kit using Muse^® Cell Analysis. The histogram represents the mean, (n = 3, triplicate). *P < 0.05 compared to control, VCX=0 μM, (ANOVA followed by SNK test).